Trial
NCT01263418
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
GlaxoSmithKline
Condition
Lymphoma, Non-Hodgkin
Intervention
Ofatumumab
Why stopped
No patients enrolled and funding has been withdrawn.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-12